GlobeNewswire: Moleculin Biotech, Inc. Contains the last 10 of 33 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T07:56:18ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/02/21/1739896/0/en/Moleculin-Biotech-Inc-Reports-Financial-Results-for-the-Year-Ended-December-31-2018.html?f=22&fvtc=4&fvtv=47656Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 20182019-02-21T21:59:00Z<![CDATA[HOUSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the year ended December 31, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developments.]]>https://www.globenewswire.com/news-release/2019/02/20/1738250/0/en/Moleculin-Announces-Outlicensing-Deal-To-Accelerate-Preclinical-and-Clinical-Development.html?f=22&fvtc=4&fvtv=47656Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development2019-02-20T12:30:00Z<![CDATA[HOUSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into a sublicense agreement with WPD Pharmaceuticals (WPD), located in Poland.]]>https://www.globenewswire.com/news-release/2019/02/07/1712050/0/en/Moleculin-Announces-Approval-for-Third-Drug-to-Commence-Clinical-Trials.html?f=22&fvtc=4&fvtv=47656Moleculin Announces Approval for Third Drug to Commence Clinical Trials2019-02-07T12:30:00Z<![CDATA[MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials]]>https://www.globenewswire.com/news-release/2019/02/05/1710486/0/en/Moleculin-Announces-the-FDA-has-Granted-Orphan-Drug-Designation-for-its-Brain-Tumor-Drug.html?f=22&fvtc=4&fvtv=47656Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug2019-02-05T12:30:00Z<![CDATA[HOUSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor.]]>https://www.globenewswire.com/news-release/2019/01/17/1701204/0/en/Moleculin-Announces-Dr-James-L-Abbruzzese-Chief-of-Medical-Oncology-Division-at-Duke-University-Joins-Science-Advisory-Board.html?f=22&fvtc=4&fvtv=47656Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board2019-01-17T12:30:00Z<![CDATA[Dr. Abbruzzese to add significant pancreatic cancer expertise to advance drug development Dr. Abbruzzese to add significant pancreatic cancer expertise to advance drug development]]>https://www.globenewswire.com/news-release/2019/01/09/1682683/0/en/Moleculin-Announces-Patient-Recruitment-Begins-in-Annamycin-Clinical-Trial-In-Poland.html?f=22&fvtc=4&fvtv=47656Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland2019-01-09T12:30:00Z<![CDATA[Received European approval to ship Annamycin into Poland to start treating patients]]>https://www.globenewswire.com/news-release/2019/01/03/1680038/0/en/Moleculin-Announces-Positive-Data-for-its-Pancreatic-Cancer-Drug-Candidate.html?f=22&fvtc=4&fvtv=47656Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate2019-01-03T12:30:00Z<![CDATA[WP1732 now second lead drug demonstrating enhanced activity in combination with immune checkpoint blockade antibodies WP1732 now second lead drug demonstrating enhanced activity in combination with immune checkpoint blockade antibodies]]>https://www.globenewswire.com/news-release/2018/12/11/1665034/0/en/REMINDER-Moleculin-Announces-Conference-Call-to-Discuss-Recent-Breakthrough-Discovery-and-FDA-Filing-on-Wednesday-December-12-2018.html?f=22&fvtc=4&fvtv=47656REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 20182018-12-11T12:30:00Z<![CDATA[HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a reminder it will host a conference call to discuss the recent discovery of a use of one of its molecules for cancer treatment and provide a business update. The call will be at 4:30 p.m. ET on Wednesday, December 12, 2018.]]>https://www.globenewswire.com/news-release/2018/12/06/1663467/0/en/Moleculin-Announces-Conference-Call-to-Discuss-FDA-Filing-and-New-Immune-Checkpoint-Data-on-Wednesday-December-12-2018.html?f=22&fvtc=4&fvtv=47656Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 20182018-12-06T21:05:00Z<![CDATA[HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it will host a conference call to discuss the recent discovery of a use of one its molecule for cancer treatment and provide a business update. The call will be at 4:30 p.m. ET on Wednesday, December 12, 2018.]]>https://www.globenewswire.com/news-release/2018/12/06/1662966/0/en/Moleculin-Announces-FDA-Filing-for-Orphan-Drug-Designation-for-Glioblastoma-Drug.html?f=22&fvtc=4&fvtv=47656Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug2018-12-06T12:30:00Z<![CDATA[HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has filed a request with the U.S. Food and Drug Administration (“FDA”) for Orphan Drug Status for its drug candidate WP1066.]]>